{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:58:10Z","timestamp":1791619090215,"version":"4.3.4"},"reference-count":66,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Venous thromboembolism (VTE) remains a major cause of cardiovascular morbidity and mortality worldwide, and is a staple of daily clinical practice. While we have seen significant advancements in therapeutics over the last 20 years, several questions and controversies remain in the selection and duration of available therapies, as well as balancing the consequences of VTE and the bleeding risk imposed by treatment modalities. In recent years, new evidence based on randomized trials and registries have reshaped the therapeutic landscape. This narrative review synthesizes the latest advancements and future directions in VTE care, including recent guideline updates, new evidence pertaining to established pharmacologic therapy, risk stratification, interventional and procedural options, and special populations including the management of cancer-associated thrombosis, and the emerging promise of factor XI inhibition. In diagnostics, the field is moving beyond traditional methods with the investigation of novel biomarkers from proteomic and metabolomic studies and the clinical implementation of advanced imaging modalities like photon-counting CT, which offers superior resolution at lower radiation doses. Artificial intelligence is emerging as a transformative tool, potentially enhancing diagnostic accuracy in imaging. Ultimately, this review will assist clinicians in integrating evolving evidence with patient-centered decision-making to maximize benefit while minimizing harm and treating the diverse and common clinical problems of VTE.<\/jats:p>","DOI":"10.3390\/jcm14217668","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T03:44:39Z","timestamp":1761795879000},"page":"7668","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["New Horizons in Venous Thromboembolism Management: A Narrative Review"],"prefix":"10.3390","volume":"14","author":[{"given":"Wassim","family":"Bedrouni","sequence":"first","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Bedrouni","sequence":"additional","affiliation":[{"name":"Department of Medicine, McGill University, Montreal, PQ H3A 3H3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Douketis","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada"},{"name":"St. Joseph\u2019s Healthcare Hamilton, Room F-544, 50 Charlton Ave East, Hamilton, ON L8N 4A6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest."},{"key":"ref_2","first-page":"3","article-title":"The epidemiology of venous thromboembolism","volume":"14","author":"Heit","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1161\/ATVBAHA.124.320151","article-title":"Global health burden of venous thromboembolism","volume":"44","author":"Wendelboe","year":"2024","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaccao.2021.03.001","article-title":"Venous and arterial thromboembolism in patients with cancer: JACC: CardioOncology state-of-the-art review","volume":"3","author":"Gervaso","year":"2021","journal-title":"JACC CardioOncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa1615066","article-title":"Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis","volume":"377","author":"Vedantham","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1801915","DOI":"10.1183\/13993003.01915-2018","article-title":"Chronic thromboembolic pulmonary hypertension","volume":"53","author":"Kim","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.thromres.2015.11.033","article-title":"The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs","volume":"137","author":"Grosse","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1182\/bloodadvances.2024015328","article-title":"American Society of Hematology\/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients","volume":"9","author":"Monagle","year":"2025","journal-title":"Blood Adv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.6004\/jnccn.2024.0046","article-title":"NCCN Guidelines Insights: Cancer-associated venous thromboembolic disease, Version 2.2024","volume":"22","author":"Streiff","year":"2024","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/EJA.0000000000002025","article-title":"European guidelines on peri-operative venous thromboembolism prophylaxis: First update. Executive summary","volume":"41","author":"Samama","year":"2024","journal-title":"Eur. J. Anaesthesiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.7326\/0003-4819-158-2-201301150-00003","article-title":"Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis","volume":"158","author":"Linkins","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"145259","DOI":"10.1016\/j.ijbiomac.2025.145259","article-title":"P-selectin and E-selectin: Key macromolecules in thrombus formation and resolution","volume":"13","author":"Yadav","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Oblitas, C.M., Galeano-Valle, F., Lago-Rodr\u00edguez, M.O., L\u00f3pez-Rubio, M., Baltasar-Corral, J., Garc\u00eda-G\u00e1miz, M., Zamora-Trillo, A., Walther, L.-A.A.-S., and Demelo-Rodr\u00edguez, P. (2024). The potential role of CA-125 as a biomarker for short-term mortality risk in patients with acute symptomatic pulmonary embolism. J. Clin. Med., 13.","DOI":"10.3390\/jcm13123601"},{"key":"ref_14","first-page":"1","article-title":"Theophilus Pius Cancer-associated venous thromboembolism and P-selectin: A review","volume":"18","author":"Kingsley","year":"2024","journal-title":"Oncol. Radiother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"104867","DOI":"10.1016\/j.ijnurstu.2024.104867","article-title":"External validation of the Khorana score for the prediction of venous thromboembolism in cancer patients: A systematic review and meta-analysis","volume":"159","author":"Huang","year":"2024","journal-title":"Int. J. Nurs. Stud."},{"key":"ref_16","first-page":"120","article-title":"Identifying novel biomarkers using proteomics to predict cancer-associated thrombosis","volume":"3","author":"Turizo","year":"2024","journal-title":"Bleeding Thromb. Vasc. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1055\/a-2330-1371","article-title":"Circulating blood biomarkers and risk of venous thromboembolism in cancer patients: A systematic review and meta-analysis","volume":"124","author":"Roy","year":"2024","journal-title":"Thromb. Haemost."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12967-024-04883-8","article-title":"Acute venous thromboembolism plasma and red blood cell metabolomic profiling reveals potential new early diagnostic biomarkers: Observational clinical study","volume":"22","author":"Febra","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e038782","DOI":"10.1161\/JAHA.124.038782","article-title":"Thrombosis, translational medicine, and biomarker research: Moving the needle","volume":"14","author":"Shaw","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s11604-025-01811-8","article-title":"Comprehensive review of pulmonary embolism imaging: Past, present and future innovations in computed tomography and other diagnostic techniques","volume":"43","author":"Triggiani","year":"2025","journal-title":"Jpn. J. Radiol."},{"key":"ref_21","first-page":"e77742","article-title":"Multiorgan ultrasound for the diagnosis of submassive pulmonary embolism in a critically ill patient","volume":"17","author":"Khairallah","year":"2025","journal-title":"Cureus"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.thromres.2024.04.016","article-title":"Modern imaging of acute pulmonary embolism","volume":"238","author":"Kroft","year":"2024","journal-title":"Thromb. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1007\/s00330-024-10992-1","article-title":"Photon-counting CT for pulmonary embolisms\u2014When radiologists don\u2019t have to choose between image quality or motion artifacts","volume":"34","author":"Andersen","year":"2024","journal-title":"Eur. Radiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1159\/000545760","article-title":"Artificial intelligence and venous thromboembolism: A narrative review of applications, benefits, and limitations","volume":"148","author":"Mudrik","year":"2025","journal-title":"Acta Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ammari, S., Camez, A.O., Ayobi, A., Quenet, S., Zemmouri, A., Mniai, E.M., Chaibi, Y., Franciosini, A., Clavel, L., and Bidault, F. (2024). Contribution of an artificial intelligence tool in the detection of incidental pulmonary embolism on oncology assessment scans. Life, 14.","DOI":"10.20944\/preprints202409.1207.v1"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"324","DOI":"10.2214\/AJR.22.28949","article-title":"Radiologist worklist reprioritization using artificial intelligence: Impact on report turnaround times for CTPA examinations positive for acute pulmonary embolism","volume":"221","author":"Batra","year":"2023","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jacbts.2024.12.004","article-title":"Recent pathophysiological insights are advancing the treatment of venous thromboembolism","volume":"10","author":"Singh","year":"2025","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_28","unstructured":"Allan, O. (2025, August 04). ISTH 2025: Apixaban Superior to Rivaroxaban for Acute VTE. The Limbic (Haematology). Available online: https:\/\/thelimbic.com\/haematology\/isth-2025-apixaban-superior-to-rivaroxaban-for-acute-vte\/."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1519869","DOI":"10.3389\/fphar.2024.1519869","article-title":"Efficacy and safety of anticoagulants on venous thromboembolism: A systematic review and network meta-analysis of randomized controlled trials","volume":"15","author":"Fu","year":"2025","journal-title":"Front. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaccao.2023.10.009","article-title":"Comparing anticoagulation strategies for venous thromboembolism associated with active cancer: A systematic review and meta-analysis","volume":"6","author":"Fujisaki","year":"2024","journal-title":"JACC CardioOncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: Prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12959-025-00719-7","article-title":"Cancer-associated venous thromboembolism: A comprehensive review","volume":"23","author":"Wan","year":"2025","journal-title":"Thromb. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","article-title":"Extended reduced-dose apixaban for cancer-associated venous thromboembolism","volume":"392","author":"Mayeur","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"979911","DOI":"10.3389\/fmed.2022.979911","article-title":"Anticoagulant for treatment and prophylaxis of venous thromboembolism patients with renal dysfunction: A systematic review and network meta-analysis","volume":"9","author":"Fan","year":"2022","journal-title":"Front. Med."},{"key":"ref_36","first-page":"111","article-title":"Efficacy and safety of novel anticoagulant therapies in patients with chronic kidney disease: A systematic review and meta-analysis","volume":"38","author":"Espinosa","year":"2025","journal-title":"J. Nephrol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000535546","article-title":"Anticoagulation in patients with chronic kidney disease","volume":"55","author":"Elenjickal","year":"2024","journal-title":"Am. J. Nephrol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"104246","DOI":"10.1016\/j.lpm.2024.104246","article-title":"Elderly patients with venous thromboembolism: Insights from the RIETE registry","volume":"53","author":"Mismetti","year":"2024","journal-title":"Presse Med."},{"key":"ref_39","unstructured":"Potere, N. (2024, January 22\u201326). Reduced-dose direct oral anticoagulants for the extended treatment of venous thromboembolism: Results from the GARFIELD-VTE Registry [conference presentation]. Proceedings of the ISTH 2024 Congress, Bangkok, Thailand. Available online: https:\/\/academy.isth.org\/isth\/2024\/isth-2024-congress\/4137581\/nicola.potere.reduced-dose.direct.oral.anticoagulants.for.the.extended.html."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1160\/TH16-04-0335","article-title":"Global Anticoagulant Registry in the Field\u2014Venous Thromboembolism (GARFIELD-VTE): Rationale and design","volume":"116","author":"Weitz","year":"2016","journal-title":"Thromb. Haemost."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/15385744241253201","article-title":"Efficacy and safety of direct oral anticoagulants for acute treatment of venous thromboembolism in older adults: A network meta-analysis of randomised controlled trials","volume":"58","author":"Kessler","year":"2024","journal-title":"Vasc. Endovasc. Surg."},{"key":"ref_42","unstructured":"Thrombosis Canada (2025, July 12). Pregnancy: Venous Thromboembolism Treatment. Available online: https:\/\/thrombosiscanada.ca\/clinical-guides\/pregnancy-venous-thromboembolism-treatment."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1182\/blood.2019000963","article-title":"How I treat venous thromboembolism in pregnancy","volume":"136","author":"Middeldorp","year":"2020","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Malik, A., Ha, N.B., and Barnes, G.D. (2024). Choice and duration of anticoagulation for venous thromboembolism. J. Clin. Med., 13.","DOI":"10.3390\/jcm13010301"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"903029","DOI":"10.3389\/fcvm.2022.903029","article-title":"Factor XI inhibitors for prevention and treatment of venous thromboembolism: A review on the rationale and update on current evidence","volume":"9","author":"Nopp","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/jth.15628","article-title":"Factor XI as a target for preventing venous thromboembolism","volume":"20","author":"Gailani","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_48","unstructured":"Anthos Therapeutics (2025, July 12). Our Science. Available online: https:\/\/www.anthostherapeutics.com\/our-science\/."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1056\/NEJMoa2406674","article-title":"Abelacimab versus rivaroxaban in patients with atrial fibrillation","volume":"392","author":"Ruff","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: The FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1016\/j.jtha.2023.04.037","article-title":"DS-1040 Study Group Inhibition of thrombin-activatable fibrinolysis inhibitor via DS-1040 to accelerate clot lysis in patients with acute pulmonary embolism: A randomized phase 1b study","volume":"21","author":"Vanassche","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"ref_52","unstructured":"Jeong, S.Y. (2025, July 12). Novel \u03b12-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial, Available online: https:\/\/reporter.nih.gov\/project-details\/10443870."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1161\/CIRCULATIONAHA.124.072364","article-title":"Large-bore mechanical thrombectomy versus catheter-directed thrombolysis in the management of intermediate-risk pulmonary embolism: Primary results of the PEERLESS randomized controlled trial","volume":"151","author":"Jaber","year":"2025","journal-title":"Circulation"},{"key":"ref_54","unstructured":"Jaber, W.A., and Secemsky, E.A. (2025). Peripheral Matters: Putting the PEERLESS Trial in Perspective. Cardiology Magazine, American College of Cardiology. Available online: https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2025\/03\/01\/01\/Peripheral-Matters-Putting-the-PEERLESS-Trial-in-Perspective."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ahj.2022.05.011","article-title":"Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study","volume":"251","author":"Klok","year":"2022","journal-title":"Am. Heart J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s11239-015-1312-5","article-title":"Guidance for the prevention and treatment of the post-thrombotic syndrome","volume":"41","author":"Kahn","year":"2016","journal-title":"J. Thromb. Thrombolysis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e018973","DOI":"10.1161\/JAHA.120.018973","article-title":"CAVA (Ultrasound-Accelerated Catheter-Directed Thrombolysis on Preventing Post-Thrombotic Syndrome) trial: Long-term follow-up results","volume":"10","author":"Notten","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s00270-024-03784-z","article-title":"Current evidence for endovascular therapies in the management of acute deep vein thrombosis","volume":"47","author":"Plotnik","year":"2024","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_59","unstructured":"Argon Medical (2025, July 12). Argon Medical Launches CLEANER\u2122 Vac Thrombectomy System to Remove Blood Clot in the Peripheral Venous Vasculature. Available online: https:\/\/www.argonmedical.com\/argon-medical-launches-cleaner-vac-thrombectomy-system-to-remove-blood-clot-in-the-peripheral-venous-vasculature\/."},{"key":"ref_60","unstructured":"AngioDynamics (2025, July 12). AngioVac System. Available online: https:\/\/www.angiodynamics.com\/product\/angiovac\/."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3400\/avd.oa.22-00108","article-title":"External validation of the Padua and IMPROVE-VTE risk assessment models for predicting venous thromboembolism in hospitalized adult medical patients: A retrospective single-center study in Japan","volume":"16","author":"Arakaki","year":"2023","journal-title":"Ann. Vasc. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: A systematic review and meta-analysis","volume":"104","author":"Mulder","year":"2019","journal-title":"Haematologica"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1182\/bloodadvances.2025016044","article-title":"Validation of risk assessment models for venous thromboembolism in patients with cancer receiving systemic therapies","volume":"9","author":"Englisch","year":"2025","journal-title":"Blood Adv."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1016\/j.jtha.2024.06.025","article-title":"Development and internal validation of the Cleveland Clinic Bleeding Model to predict major bleeding risk at admission in medical inpatients","volume":"22","author":"Mittman","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1186\/s12911-024-02834-3","article-title":"A new risk assessment model of venous thromboembolism by considering fuzzy population","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Med. Inform. Decis. Mak."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0140-6736(23)02369-3","article-title":"Targeted prophylactic anticoagulation based on the TRiP(cast) score in patients with lower limb immobilisation: A multicentre, stepped wedge, randomised implementation trial","volume":"403","author":"Douillet","year":"2024","journal-title":"Lancet"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/21\/7668\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T04:10:42Z","timestamp":1761797442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/21\/7668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":66,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["jcm14217668"],"URL":"https:\/\/doi.org\/10.3390\/jcm14217668","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]}}}